184 related articles for article (PubMed ID: 19167889)
1. Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.
Vandervelde L; Van den Bergh PY; Goemans N; Thonnard JL
Neuromuscul Disord; 2009 Feb; 19(2):99-103. PubMed ID: 19167889
[TBL] [Abstract][Full Text] [Related]
2. A comparison between self-reported and observed activity limitations in adults with neuromuscular disorders.
Vandervelde L; Dispa D; Van den Bergh PY; Thonnard JL
Arch Phys Med Rehabil; 2008 Sep; 89(9):1720-3. PubMed ID: 18760156
[TBL] [Abstract][Full Text] [Related]
3. Experienced and physiological fatigue in neuromuscular disorders.
Schillings ML; Kalkman JS; Janssen HM; van Engelen BG; Bleijenberg G; Zwarts MJ
Clin Neurophysiol; 2007 Feb; 118(2):292-300. PubMed ID: 17166763
[TBL] [Abstract][Full Text] [Related]
4. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders.
Vandervelde L; Van den Bergh PY; Goemans N; Thonnard JL
Neuromuscul Disord; 2007 Jun; 17(6):459-69. PubMed ID: 17433675
[TBL] [Abstract][Full Text] [Related]
5. The development of a model of fatigue in neuromuscular disorders: a longitudinal study.
Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
J Psychosom Res; 2007 May; 62(5):571-9. PubMed ID: 17467412
[TBL] [Abstract][Full Text] [Related]
6. Measurement of the functional status of patients with different types of muscular dystrophy.
Lue YJ; Lin RF; Chen SS; Lu YM
Kaohsiung J Med Sci; 2009 Jun; 25(6):325-33. PubMed ID: 19560997
[TBL] [Abstract][Full Text] [Related]
7. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.
Kennedy RA; Carroll K; McGinley JL; Paterson KL
J Foot Ankle Res; 2020 Mar; 13(1):10. PubMed ID: 32122377
[TBL] [Abstract][Full Text] [Related]
8. Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I.
Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
Acta Neurol Scand; 2007 Apr; 115(4):265-70. PubMed ID: 17376125
[TBL] [Abstract][Full Text] [Related]
9. Influence of relatives on fatigue experienced by patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I.
Kalkman JS; Schillings ML; Zwarts MJ; van Engelen BG; Bleijenberg G
Eur Neurol; 2006; 56(1):24-30. PubMed ID: 16914927
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with Charcot-Marie-Tooth disease.
Vinci P; Serrao M; Millul A; Deidda A; De Santis F; Capici S; Martini D; Pierelli F; Santilli V
Neurology; 2005 Sep; 65(6):922-4. PubMed ID: 16186535
[TBL] [Abstract][Full Text] [Related]
11. Limb girdle muscular dystrophy: an interval study of weakness and functional impairment.
Stübgen JP
J Clin Neuromuscul Dis; 2008 Mar; 9(3):333-40. PubMed ID: 18344714
[TBL] [Abstract][Full Text] [Related]
12. Disability and quality of life in individuals with muscular dystrophy.
Ahlström G; Gunnarsson LG
Scand J Rehabil Med; 1996 Sep; 28(3):147-57. PubMed ID: 8885037
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness of the motor function measure in neuromuscular diseases.
Vuillerot C; Payan C; Girardot F; Fermanian J; Iwaz J; Bérard C; Ecochard R;
Arch Phys Med Rehabil; 2012 Dec; 93(12):2251-6.e1. PubMed ID: 22705238
[TBL] [Abstract][Full Text] [Related]
14. Translation, reliability, and validity of the Norwegian version of the ABILHAND-NMD and the ACTIVLIM for Myotonic Dystrophy type 1.
Fossmo HL; Ørstavik K; Frich JC; Robinson HS
Disabil Rehabil; 2024 Jun; 46(12):2699-2707. PubMed ID: 37438996
[TBL] [Abstract][Full Text] [Related]
15. Fatigue and neuromuscular diseases.
Féasson L; Camdessanché JP; El Mandhi L; Calmels P; Millet GY
Ann Readapt Med Phys; 2006 Jul; 49(6):289-300, 375-84. PubMed ID: 16780988
[TBL] [Abstract][Full Text] [Related]
16. Pain in hereditary neuromuscular disorders and myasthenia gravis: a national survey of frequency, characteristics, and impact.
Guy-Coichard C; Nguyen DT; Delorme T; Boureau F
J Pain Symptom Manage; 2008 Jan; 35(1):40-50. PubMed ID: 17981001
[TBL] [Abstract][Full Text] [Related]
17. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
[TBL] [Abstract][Full Text] [Related]
18. How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases?
Batcho CS; Van den Bergh PY; Van Damme P; Roy AJ; Thonnard JL; Penta M;
Neuromuscul Disord; 2016 Mar; 26(3):211-20. PubMed ID: 26826887
[TBL] [Abstract][Full Text] [Related]
19. Neuropathy progression in Charcot-Marie-Tooth disease type 1A.
Shy ME; Chen L; Swan ER; Taube R; Krajewski KM; Herrmann D; Lewis RA; McDermott MP
Neurology; 2008 Jan; 70(5):378-83. PubMed ID: 18227419
[TBL] [Abstract][Full Text] [Related]
20. Assessing functional outcomes of children with muscular dystrophy and scoliosis: the Muscular Dystrophy Spine Questionnaire.
Wright JG; Smith PL; Owen JL; Fehlings D
J Pediatr Orthop; 2008 Dec; 28(8):840-5. PubMed ID: 19034175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
